It wasn’t long ago that renal denervation was poised to be the next big thing in the medical device field. But then Medtronic announced that its Symplicity system failed to meet its efficacy endpoint in a pivotal clinical trial. Medtronic held off on divulging details until recently, when it reported the findings at the American College of Cardiology meeting in Washington, D.C. and in the New England Journal of Medicine. The study was the first to pit renal denervation cohort against a sham-control group. Compared to a sham procedure, renal denervation resulted in a small benefit in patients with hypertension—a 2.39-mm Hg drop in systolic blood pressure six months after the study was launched.
Help employers find you! Check out all the jobs and post your resume.
